ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annu... ( The Phase IIa MIVI-IIT trial reported...)

HOME >> BIOLOGY >> TECHNOLOGY

ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting

Date:12/4/2007

The Phase IIa MIVI-IIT trial reported today was a sham injection controlled study in which patients were assigned to receive either 75ug or 125ug of microplasmin. A total of 30 patients across Europe were recruited to the study, of which 24 received microplasmin therapy while 6 received the sham injection. The trial showed clear benefits from therapy with 9 of the 24 microplasmin treated patients seeing resolution of their vitreomacular traction (including macular hole closure in 2 of the 4 macular hole cases) without the need for vitrectomy. In contrast, none of the 6 sham injected patients had resolution of their vitreomacular traction (including two patients with macular hole). The trial also showed that microplasmin therapy was safe and well tolerated. Given the excellent safety of microplasmin in the trial to-date, it has been decided to recruit a further 15 patients (12 treated and 3 sham) to evaluate a higher 175ug dose of the product to see if it will produce even better clinical outcomes.

Professor Peter Stalmans, the study's principal investigator, commented: "The results from the study that I will present at the ASRS meeting today clearly indicate the potential for microplasmin to become a more convenient, less invasive, hence more patient friendly treatment for vitreomacular traction. The fact that we have been able to clearly show that microplasmin can achieve clinically important outcomes such as traction release and macular hole closure without surgery augurs well for the future development of this novel treatment."

Prof. Desire Collen, CEO of ThromboGenics, commenting on today's results said: "The results of the microplasmin trial that we have announced today clearly show the drug's potential to treat a range of back of the eye diseases. The clinical benefits that we have seen in this study in conjunction with its excellent safety profile provide us with sound reasons for pushing ahead with the further clinical development of microp
'/>"/>

SOURCE ThromboGenics NV
Copyright©2007 PR Newswire.
All rights reserved

3

GOOD

Page: 1 2 3 4
Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
6. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
7. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health
8. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
9. Sangamo BioSciences Presents Data Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
10. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
11. Arpida Presents Preclinical Data on AR-2474 at ICAAC

Post Your Comments:

(Date:12/17/2009)... Top 10 Health Industry Issues in 2010, puts healthcare cost control ... the year ahead. , ... New York, NY ... Top 10 Health Industry Issues in 2010, puts healthcare ... overarching theme for the year ahead. , , , , ,“Healthcare ...

(Date:12/17/2009)... the latest particle size distribution technologies, including the new C35 ... AAPS 2010. , ... (PRWEB) December ... American Association of Pharmaceutical Scientists’ Annual Meeting, AAPS 2010 ... Booth 612 at AAPS 2010 to see the latest particle ...

(Date:12/16/2009)... of East Anglia (UEA) could contribute to the development ... generate clean electricity. , Published today by the leading ... Sciences (PNAS), the researchers have demonstrated for the ... by ,breathing rocks,. , The findings could be applied ... such as fuel cells, or ,bio-batteries, powered by animal ...

(Date:12/16/2009)... Corporation (Nasdaq: MATK ) today announced its financial ... October 31, 2009. Revenues for the fourth quarter were ... fourth quarter of fiscal 2008. Net income was $11.0 ... quarter of fiscal 2009, a 5% increase compared with ... year,s fourth quarter. The fourth quarter of fiscal ...

[0] Squeezing Costs out of Healthcare Tops PricewaterhouseCoopers' List of Health Industry Issues in 2010,[0] Particle Size Distribution Technologies at American Association of Pharmaceutical Scientists (AAPS) Annual Meeting 2010 [0] 'Rock-breathing' bacteria could generate electricity and clean up oil spills [0] Martek Announces Fourth Quarter and FY 2009 Financial Results

... SERIES Episode #9 - HEART DISEASE September 19, 2007, NEW YORK, Sept. ... upcoming episode of the Charlie Rose Science Series will ... cause of mortality worldwide. A ... biology and genetics of the disease, prevention and treatment, the ...

... HAMBURG, Germany, Sept. 14 Indivumed announces today,that ... signed. Within,this agreement Indivumed will apply its automated ... targets in the,area of oncology. Indivumed will provide ... from its tumor biobank as well as specifically,collected ...

... Inc. (Nasdaq: HGSI ) announced today that its ... Conference in London,will be webcast and may be accessed ... ) A member of Human Genome Sciences, senior ... Tuesday, September 18, 2007 at 2:20 pm London,Time, or ...

Other Biology Technology:Panel to Discuss the Far-Ranging Effects and Consequences of Heart Disease, Which is the Leading Killer in Both Men and Women in the United States 2

Panel to Discuss the Far-Ranging Effects and Consequences of Heart Disease, Which is the Leading Killer in Both Men and Women in the United States Indivumed Supports Roche Diagnostics With Immunohistochemistry Services and Clinical Specimens for Biomarker Discovery and Drug Development Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference

(Date:12/16/2009)... The new "Climate Knowledge and Innovation Community (Climate-KIC)" is ... Budapest. The Climate-KIC program brings together the expertise of ... a step-change in Europe,s innovation capacity to meet the ... to prepare for a new low-carbon society. In responding ... to how we produce, distribute, and consume goods, and ...

(Date:12/16/2009)... Bank is a vital source of financial and technical ... glance, this may not appear to be connected to ... of Earth,s environment are intrinsically linked. , Global climate ... poverty and advancing development in the poorest countries and ... , These factors have led to a growing demand ...

(Date:12/16/2009)... Bacteria inhabited our planet for more than 4 billion ... us by as many eons more. That suggests they ... from Tel Aviv University bacteria expert Prof. Eshel Ben-Jacob ... and Astronomy, grounded in the study of bacteria, presents ... why most people should not automatically opt for the ...

Breaking Biology News(10 mins):Innovation boost to tackle climate change 2 Innovation boost to tackle climate change 3 ESA and World Bank move toward closer collaboration 2 ESA and World Bank move toward closer collaboration 3 ESA and World Bank move toward closer collaboration 4 Bacteria wouldn't opt for a swine flu shot 2 Bacteria wouldn't opt for a swine flu shot 3 For Profit Health Care Contracts Jeopardizing the Strength of the VA Union Says 58552 1 For Profit Health Care Contracts Jeopardizing the Strength of the VA Union Says 58552 2 For Profit Health Care Contracts Jeopardizing the Strength of the VA Union Says 58552 3 Intarcia Therapeutics Inc Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabe 14300 1 Intarcia Therapeutics Inc Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabe 14300 2 Intarcia Therapeutics Inc Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabe 14300 3 Intarcia Therapeutics Inc Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabe 14300 4 Intarcia Therapeutics Inc Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabe 14300 5 The National Park Foundation and Olympus Announce Winner of the First Ever Your Parks Video Challenge 14298 1 The National Park Foundation and Olympus Announce Winner of the First Ever Your Parks Video Challenge 14298 2 The National Park Foundation and Olympus Announce Winner of the First Ever Your Parks Video Challenge 14298 3 The National Park Foundation and Olympus Announce Winner of the First Ever Your Parks Video Challenge 14298 4

[0] Innovation boost to tackle climate change [0] ESA and World Bank move toward closer collaboration [0] Bacteria wouldn't opt for a swine flu shot

... , A novel x-ray technique allowing the observation of ... been developed by a team of researchers from EPFL and ... research led by Professor Majed Chergui, head of EPFL,s laboratory ... PSI appear online December 11 in the journal Science ...

... impacts on the environment have reduced populations of ... this more apparent than in worldwide fisheries, where ... and populations of fish are on the brink ... the dire situation, captive breeding, the controlled breeding ...

... top food scientist at Queen,s University Belfast is playing a ... techniques to detect chemical contaminants in food and animal feed. ... and Land Use at Queen,s, will lead a team of ... from potentially fatal toxins in a wide range of foods ...

Other Biology News:Molecules in the spotlight 2 Queen's University Belfast plays leading role in Europe-wide tests for safer food 2

Molecules in the spotlight A fisheries catch-22 Queen's University Belfast plays leading role in Europe-wide tests for safer food

... The Lambda 10-2 is a ... Its impressive speed coupled with exceptionally ... ideal for research applications involving fluorescence ... or any application requiring rapid and ...

...

... Enzymatic method stops PCR carry-over contamination, ... to degrade PCR products from previous ... acid templates, which improves amplification ,Optimized ... reagents and GeneAmp instrument systems , ...

...

Biology Products:

Lambda 10-2 Filter Wheel from AutoMate Scientific, Inc Wellwash AC Big Bottles (100-240 V) from Thermo Scientific GeneAmp PCR Carry-over Prevention Kit from Applied Biosystems Wellwash 4 Mk 2 from Thermo Scientific

ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annu...( The Phase IIa MIVI-IIT trial reported...)